1. Fujiwara Y, Heidelberger C (1970) Fluorinated pyrimidines. XXXVII. The incorporation of 5-trifluoromethyl-2′-deoxyuridine into the deoxyribonucleic acid vaccinia virus. Mol Pharmacol 6:281–291
2. Fujiwara Y, Oki T, Heidelberger C (1970) Fluorinated pyrimidines. XXXVII. Effect of 5-trifluoromethyl-2′-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol 6:273–280
3. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, Yamada Y, Asao T (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 59:1227–1236
4. Green MC, Pusztai L, Theriault LR, Adinin RB, Hofweber M, Fukushima M, Mita A, Bindra N, Hortobagyi GN (2006) Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol ASCO Annu Meet Proc Part I 24:10576
5. Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107:1383–1390